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Endocytosis inhibitorCell-penetrating peptides (CPPs) have shown great potency for cargo delivery both in vitro and in vivo.
Different biologically relevant molecules need to be delivered into appropriate cellular compartments in
order to be active, for instance certain drugs/molecules, e.g. antisense oligonucleotides, peptides, and
cytotoxic agents require delivery into the cytoplasm. Assessing uptake mechanisms of CPPs can help to
develop novel and more potent cellular delivery vectors, especially in cases when reaching a speciﬁc
intracellular target requires involvement of a speciﬁc internalization pathway. Here we measure the overall
uptake kinetics, with emphasis on cytoplasmic delivery, of three cell-penetrating peptides M918, TP10 and
pVec using a quenched ﬂuorescence assay. We show that both the uptake levels and kinetic constants
depend on the endocytosis inhibitors used in the experiments. In addition, in some cases only the
internalization rate is affected by the endocytosis inhibitors while the total uptake level is not and vice versa,
which emphasizes importance of kinetic studies when assessing the uptake mechanisms of CPPs. Also, there
seems to be a correlation between lower total cellular uptake and higher ﬁrst-order rate constants.
Furthermore, this may indicate simultaneous involvement of different endocytic pathways with different
efﬁcacies in the internalization process, as hypothesized but not shown earlier in an uptake kinetics assay.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Cell-penetrating peptides are short cationic and/or amphipathic
peptides that are able to transport various molecules into mammalian
cells. After the discovery of the ﬁrst CPPs, Anntennapedia-derived
peptide, now known as penetratin [1] and Tat peptide [2] the research
in this ﬁeld has been highly active since CPPs have shown great
potency in cargo delivery both in vitro and in vivo [3–7].
Many novel CPPs have been developed in search for more
effective transport vectors and there are even attempts made to
predict cell-penetrating sequences [8]. Several CPP targeting schemes
have been developed in order to turn these vectors into cell-speciﬁc
cargo carriers [9–11].
Over the years several internalization mechanisms have been
proposed to be involved in CPP uptake, ranging from direct
translocation, transient pore formation and inverted micelle models
to various subtypes of endocytosis, as shortly reviewed in [3].
Whereas non-endocytic translocation of CPPs without cargo mole-
cules has been reported [12,13] the consensus among researchers
appears to be that various types of endocytosis are exploited in the
uptake of larger CPP-cargo constructs, and that several cell-entryof Technology, Nooruse 1-517,
ll rights reserved.mechanisms might act in parallel [14–17]. Also, it has been shown
that the uptake can depend on whether the CPP is labeled or not, the
type of cargo molecule used, and where the cargo is positioned in the
CPP [18]. Further, it is important to take into consideration how the
uptake is registered–whether a biological effect (e.g. splice correc-
tion) or just intracellular ﬂuorescence of the labeled CPPs is
measured–especially when the delivery of therapeutic molecules is
under investigation since high total uptake level is not necessarily
correlating with the biological effect of the cargo [19].
Several drugs and bioactive molecules need to reach the cytosol in
order to mediate their biological effect [20–21]. Therefore, it is
essential to evaluate which CPPs would be the best candidates for
cytoplasmic delivery in terms of total uptake. Also, assessing the
uptake mechanisms is of great importance since knowing the
mechanisms facilitates the development of novel and more potent
CPPs. Simple end-point uptake measurements in presence of
endocytosis inhibitors may not reﬂect the inhibition effects precisely
because if a certain inhibitor only affects the rate of uptake, the
inhibition effect will depend largely on the chosen end-point. By
registering also the uptake kinetics some more light might be shed on
the possible internalization mechanisms of CPPs since one more
parameter–the ﬁrst-order rate constant of the uptake–will be
revealed in these experiments. To our knowledge no attempts have
been made so far to quantify the effect of endocytosis inhibitors on
real time uptake kinetics.
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delivery kinetics, with emphasis on cytoplasmic delivery, of three
established CPPs M918, TP10 and pVec. We measured the uptake
kinetics using a quenched ﬂuorescence assay [22] with some
modiﬁcations. The results show that the uptake levels and rate
constants depend on the endocytosis inhibitors used in the experi-
ments and that, surprisingly, lower uptake levels often correlate with
higher ﬁrst-order rate constants. This may indicate simultaneous
involvement of different endocytic pathways in the uptake of CPPs.
2. Experimental procedures
2.1. Peptide synthesis
Cargo peptide, TP10, and pVec were synthesized stepwise on ABI
433A peptide synthesizer on 4-methylbenzhydrylamine (MBHA)
resin using t-Boc chemistry. Amino acids were coupled as HOBt
(hydroxybenzotriazole) esters using DCC (N,N'-dicyclohexylcarbodii-
mide) and DIEA (N,N'-Diisopropylethylamine). TheM918 peptide was
synthesized stepwise on ABI 433A (Applied Biosystems) synthesizer
on rink amide MBHA resin using Fmoc chemistry. Amino acids were
coupled as HOBt (hydroxybenzotriazole) esters using TBTU (2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetraﬂuoroborate)
and DIEA (N,N'-Diisopropylethylamine). In order to facilitate disulﬁde
coupling, additional Cys(NPys) was manually coupled to the cargo
peptide and a Cys residue was coupled to the N-termini of M918 and
pVec, and to the ɛ-amino group on Lys7 of TP10. The cargo peptidewas
thereafter manually labeled N-terminally with a ﬂuorescent molecule
Abz (2-amino benzoic acid) and His(DNP) was coupled manually to
the last cysteine of the CPPs to allow the DNP (dinitrophenol) moiety
to act as a quencher for the Abz group. For peptide sequences see
Table 1. After cleaving the peptides from the solid support, ﬁnal
products were puriﬁed with a reverse phase HPLC Supelco C18
column by using Dionex HPLC system, and the correct molecular
masses were veriﬁed using Perkin-Elmer prOTOF 2000 MALDI O-TOF
mass spectrometer.
2.2. Conjugation of the cargo peptide and CPPs
Abz-C(NPys)-Cargo peptide and His(DNP)-C-CPPs were conjugat-
ed via a disulﬁde bond. The reaction was carried out in DMF (N,N-
dimethylformamide) supplemented with 10% DMSO (dimethyl
sulfoxide) for 4 h. Thereafter, cargo-SS-CPP conjugates were puriﬁed
with a reverse phase HPLC Supelco C18 column by using Dionex HPLC
system, and the correct molecular mass veriﬁed using Perkin-Elmer
prOTOF 2000 MALDI O-TOF mass spectrometer.
2.3. Cell culture
HeLa cells were grown in DMEM (Dulbecco's modiﬁed Eagle's
medium) with glutamax, supplemented with 0.1 mM non-essential
amino acids, 1.0 mM sodium pyruvate, 10% FBS (fetal bovine serum),
100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were grown







a Underlined amino acids mark position where His(DNP)-Cys moiety is coupled to.
For structures see Fig. 1A.2.4. Endocytosis inhibitors
In order to assess internalization mechanisms of the cargo-SS-CPP
constructs, the following endocytosis inhibitors were used: 10 μM
chlorpromazine, 4 μM cytochalasin D, 50 nM wortmannin, 0.4 M
sucrose. Cytochalasin D was used to block actin polymerization and
hence the formation of macropinosomes [23], and wortmannin was
used to inhibit clathrin mediated endocytosis by inhibiting PI3-kinase
[23]. Both chlorpromazine [24] and sucrose [25] were utilized in order
to inhibit clathrin mediated endocytosis. Chloroquine, a widely used
endosomolytic agent, was left out of this study due to high inter-
ference with the ﬂuorescent readout.
2.5. Uptake kinetics experiments
Two days prior to experiment HeLa cells were seeded onto a 10-cm
cell culture dish to reach 90% conﬂuency on the day of the experiment.
Before treatment with peptides, cells were washed with PBS
(phosphate buffered saline) and detached from the culture dish by
incubating in 1ml solution of 3mMEDTA (ethylenediaminetetraacetic
acid). Then 4ml of DMEMsupplementedwith 10% FBSwas added after
which the cells were counted. Cells were centrifuged at 500×g for
10 min, supernatant was removed and the cells were resuspended in
HKR (HEPES-buffered Krebs–Ringer solution) supplemented with
1 mg/ml glucose (HKRg) to have approximately 2.5×106 cells/ml
(1.25×105 cells in 50 μl).
Kinetic measurements were performed in white 96-well plates
according to the following protocol. 150 μl of the cargo-SS-CPP
conjugates, prepared and diluted in HKRg, were added to the wells of
the 96-well plate, while the plate was kept on ice. After 30 min
approximately 125,000 cells in 50 μl were added to each well, to reach
the ﬁnal incubation volume of 200 μl and the ﬁnal concentration of the
cargo-SS-CPP conjugates of 1, 2.5 or 5 μM. Experiments in the
presence of endocytosis inhibitors were carried out in a similar way;
but ﬁrst the suspended cells were pre-incubated for 30 min at 37 °C
with corresponding endocytosis inhibitor after which the cells were
added to each well that contained the conjugate solution with
corresponding endocytosis inhibitor.
Thereafter, the plate was transferred to SPECTRAmax GEMINI XS
(Molecular Devices, USA) ﬂuorometer and the ﬂuorescence was
measured (excitation wavelength 320 nm, emission wavelength
420 nm). All the measurements were carried out at 37 °C in
atmospheric CO2 concentration. Data points were recorded in 35 s
time interval, between eachmeasurement the platewas shaken for 5 s
to keep the cells in suspension. After 80 min the cells were lysed and
TCEP (tris(2-carboxyethyl)phosphine) was added to each well to
reach the ﬁnal concentration of 100 μM to reduce all remaining
disulﬁde bonds. The resulting signal described the ﬂuorescence level
which arises if the disulﬁde bonds between each cargo-SS-CPP
molecule are cleaved at a given concentration. These data were used
to normalize measured ﬂuorescence values and to present the uptake
data in picomoles of delivered constructs.
In order to verify weather the cargo peptide was membrane
impermeable or not in our system, a cargo peptide carrying the
quencher molecule instead of the ﬂuorophore was synthesized. This
molecule was conjugated to the original cargo peptide and the cells
were incubated with 5 μM of that construct. The same construct
served also as a negative control of the uptake.
We additionally veriﬁed that the observed cytoplasmic delivery of
the CPP-cargo constructs is not an artifact form the disulﬁde reduction
on the cell membrane or in the extracellular environment due to
possible glutathione outﬂow from the cells. For these control
experiments the cells were prepared as described above and treated
with 5 μM cargo-SS-CPP conjugates in 1.5 ml Eppendorf tubes. At
different time points (0, 30, 60 and 90min) the cells were spun down,
100 μl of supernatant was removed and mixed with 50 μl of 6 mM
Fig. 1. (A) Structure of cargo-SS-CPP construct in quenched ﬂuorescence assay. (B) A
representative sample of a cargo-SS-CPP construct in quenched ﬂuorescence assay. The
ﬂuorescence of a 10 μM sample in HKRg (HEPES-buffered Krebs–Ringer solution,
supplemented with 1 mg/ml glucose) is measured before and after reducing the
disulﬁde bonds with TCEP. When the construct is not present then ﬂuorescence of the
buffer does not increase. The error bars indicate S.E.M., number of samples is 3.
Fig. 2. Cargo-SS-CPP uptake curves, for concentrations 1 μM (A), 2.5 μM (B) and 5 μM
(C). The curves are plotted as mean values of triplicate experiment and non-linear
regression curves according to Eq. (1).
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Ellman's reagent reacts with free thiols, releasing 2-nitro-5-thio-
benzoate (TNB−), which ionizes to yellow TNB2−. By monitoring
absorption at 405 nm at various time points it can be demonstrated
weather the free thiol concentration in the extracellular media is
increasing or not. The absorption was measured in triplicates on a 96-
well plate using a Tecan Sunrise microplate absorbance reader (Tecan
Group Ltd., Switzerland). The data were normalized to the absorbance
of the DTNB treated supernatant of lysed cells.
3. Results
Measurement of Abz-Cys-LKANL-amide pentapeptide uptake
kinetics mediated by selected CPPs was described by Hällbrink et al.
[22]. This assay is based on measurement of the increase in
ﬂuorescence using an energy transfer quenching method where the
Abz molecule acts as a ﬂuorophore and nitrotyrosine acts as a
quencher [22]. However, in that work the CPP-mediated uptake
mechanisms were not elucidated and the uptake kinetics was
measured on different set of CPPs.
In the current work the quencher is changed. The side chain
protective group of His, DNP, was used as a quencher in order to
increase synthesis yields (Fig. 1A). In principle, when Abz-labeled
cargo and CPP are conjugated via a disulﬁde linker, the Abz and DNP
molecules are in close proximity, and the ﬂuorescence of the Abz
molecule (excitation: 320 nm, emission: 420 nm) is quenched by the
DNP component. Once the disulﬁde bridge is cleaved, the ﬂuorophore
and quencher will drift apart and increase of ﬂuorescence signal is
registered. This is shown in Fig. 1B where 10 μM cargo-SS-CPP
construct in HKRg is treated with 100 μM TCEP. The data is
represented as fold increase in ﬂuorescence signal before and after
TCEP treatment. Intracellularly the disulﬁde bond is reduced by
glutathione and increase in ﬂuorescence signal reﬂects the overall
uptake arising from released cargo molecules.
We evaluated three different CPPs (M918, TP10 and pVec) for their
ability to deliver pentapeptide cargo into HeLa cells with and without
the presence of endocytosis inhibitors. Uptake kinetic curves were
registered and the measured data points were ﬁtted to one-phase
exponential association curves with GraphPad Prism software
(GraphPad Software, Inc., USA), according to the formula
Y = Ymax  1− exp −K  xð Þ½  ðEq:1Þwhere Y is the uptake level (picomoles of internalized peptide), Ymax
is the maximal uptake level, K is the ﬁrst-order rate constant in s−1,
and x is time in s. The ﬁrst-order rate constants were determined from
the ﬁtted curves, as well as exponential association plateau values.
3.1. The uptake kinetics is dependent on peptide concentration
Before measuring uptake kinetics of cargo-SS-CPP constructs we
veriﬁed weather the cargo peptide was membrane impermeable or
not in our system. For this purpose we synthesized also a cargo
peptide carrying the quencher molecule instead of the ﬂuorophore.
We conjugated these two different types of cargo molecules and
incubated the cells with 5 μM of that construct. We did not observe
any increase of ﬂuorescence during 60 min incubation (data not
shown).
Not surprisingly, the peptide uptake curves depend on the peptide
concentration. The results of different experiments carried out on
different days are repeatable. The K values determined from the
experiments conducted on different days vary in range of 5%, but the
difference in plateau values is somewhat greater, reaching 10% (data
not shown), most probably depending on the actual number of
suspended cells added to the peptide solutions in the 96-well plate.
The results of the uptake experiments, performed in triplicates, at
three different conjugate concentrations (1, 2.5 and 5 μM) with the
Table 2
Uptake rate constants and plateau values.
Cargo-SS-CPP Cargo-SS-CPP concentration
1 μM 2.5 μM 5 μM
Rate constants (K±SD)×10−4 s−1
Cargo-SS-M918 2.00±0.65 (3) 6.08±0.35 (3) 5.74±0.11 (3)
Cargo-SS-TP10 13.92±0.79 (3) 5.73±0.15 (3) 4.71±0.15 (3)
Cargo-SS-pVec 8.48±0.37 (3) 4.31±0.10 (3) 4.98±0.20 (3)
Plateau values (Ymax±SD) pmol
Cargo-SS-M918 143.1±8.9 (3) 209.1±4.0 (3) 534.3±3.2 (3)
Cargo-SS-TP10 48.2±0.8 (3) 133.8±1.2 (3) 483.0±5.7 (3)
Cargo-SS-pVec 80.8±0.8 (3) 184.1±1.8 (3) 512.2±6.8 (3)
Fig. 4. First-order rate constants (A) and plateau values (B) of cargo-SS-CPP uptake in
presence of different endocytosis inhibitors. Experiments were carried out with
conjugate concentration of 2.5 μM. Mean values are compared with the control by one-
way ANOVA analysis; ⁎⁎⁎ marks signiﬁcant difference pb0.001, ⁎⁎ marks signiﬁcant
difference pb0.05, and ns marks statistically non-signiﬁcant difference. The error bars
indicate S.E.M., number of samples is 3.
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and Table 2.
Plateau values of the kinetic curves depend on concentration of the
conjugates (Table 2), but a general relationship can be brought out; at
each tested concentration M918 is superior to the other two, leaving
TP10 with the lowest uptake level, in context of maximal uptake. It is
notable that similar relationship does not apply for kinetic constants
since kinetic constants vary to a greater extent in relation with
concentration of the conjugates. We also observed that the free thiol
content in the extracellular media is not changing during 90 min
incubation with 5 μM cargo-SS-CPP constructs (Fig. 3).
3.2. Effect of endocytosis inhibitors on the uptake kinetics
Further on, the effect of the endocytosis inhibitors on the uptake
curves was investigated. We chose a cargo-SS-CPP concentration of
2.5 μM. This concentration of CPPs that we used in the study, relying
on the literature, is not toxic to the cells [18,26,27]. This is also
conﬁrmed by an LDH leakage assay which did not show higher
toxicity levels of peptide-treated cells compared to untreated cells
(data not shown). Cargo-SS-CPP concentration of 2.5 μM still retained
high enough ﬂuorescent signals to be measured by the ﬂuorometer.
Lowering the construct's concentration even more led to low signal-
to-noise ratio and these concentrations were left out of this study. The
inhibitors used in these experiments were 10 μM chlorpromazine,
4 μM cytochalasin D, 50 nM wortmannin, and 0.4 M sucrose; the
concentrations were chosen based on previous experience in our lab
[19,28,29]. The results of these experiments are presented in Fig. 4.
Endocytosis inhibitors affect both the ﬁrst-order rate constant and
the total uptake level of cargo-SS-CPP constructs, although the
inhibition effects vary between CPPs. For instance, the endocytosis
inhibitors have the strongest effect on M918-mediated uptake,
whereas pVec-mediated uptake is less affected by the inhibitors.
Judging from Fig. 4 there seems to be several different pathways
involved in the uptake of the conjugates that are affected by differentFig. 3. Free thiol content in the incubation media is not changed when the cells are
incubated in 5 μM cargo-SS-CPP constructs or simply in HKRg (mock-treated sample).
The experiments were carried out in triplicates. For experimental conditions, see
Experimental procedures.inhibitors to different extent. By using sucrose or wortmannin the
ﬁrst-order rate constant of M918 uptake increases, meaning that the
plateau value of the uptake is reached in shorter time interval. At the
same time the plateau values themselves in case of M918 and
mentioned inhibitors are signiﬁcantly lower compared to the control.
Interestingly, cytochalasin D does not signiﬁcantly change the kinetic
constants but nevertheless reduce the plateau value of the uptake of
M918.
For the TP10 conjugate, cytochalasin D is the only inhibitor that
does not signiﬁcantly affect the kinetic constant of the uptake while
still increasing the plateau value. Wortmannin, chlorpromazine and
sucrose increase the ﬁrst-order rate constants of the uptake and
decrease the total uptake levels.
For the pVec conjugate it is observable that only cytochalasin D has
statistically signiﬁcant effect on both the kinetic constant and plateau
value; the other inhibitors only affect the plateau values but not
kinetic constants, except wortmannin that is ineffective for both
parameters.
It is interesting that a general pattern between the kinetic constant
and plateau values seems to be emerging. When the corresponding
inhibitor increases the ﬁrst-order rate constant, the plateau value of
the uptake is decreased at the same time and vice versa, which is
somewhat surprising. On the other hand, when a kinetic constant
does not change signiﬁcantly upon treatment with a certain inhibitor
the same conclusion cannot be made for the corresponding plateau
value.
4. Discussion
So far only few studies have been conducted to quantitatively
characterize real time uptake kinetics. Previously the uptake kinetics
of 125I-biotinyl-transportan in Bowes' melanoma cells [30], NBD-
penetratin in K562 cells [31,32], [99mTc]Tat [33] and ﬂuoresceinyl-Tat
in Jurkat cells [34], and rhodamine-labeled Tat, polyarginine [35,36],
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ment of the uptake kinetics of modiﬁed ﬂuorescein-labeled poly-
arginine [37], ﬂuorescein-labeled programmed cell death inducing
cyclic hexapeptide conjugated to an arginine rich CPP [38], and
ﬂuorescein or TAMRA labeled L- or D-isomer, respectively, of
polyarginine [13] has been recently reported. However, several
different methods ranging from ﬂow cytometry studies and spectro-
photometry to meremicroscopy observations have been used in these
studies, which means that in many cases precise rate constants have
not been characterized. Our intension was to measure these
parameters in different experimental conditions in order to draw
conclusions on the mechanisms of CPP translocation.
Here we used a quenched ﬂuorescence assay [22] with small
modiﬁcations. We use CPPs that carry two additional amino acids, a
cysteine to allow disulﬁde bridging, and a histidine with dinitrophe-
nol (DNP) side protecting group which serves as a quencher for the
ﬂuorescent Abz molecule. Abz is in turn coupled to the cargo peptide
which also carries an additional cysteine for disulﬁde bridging. The
cargo peptide itself is cell impermeable [22]. The structure of the
designed constructs is presented in Fig. 1A.
Once the disulﬁde bond is cleaved, the ﬂuorophore (Abz) and
quencher (DNP) will drift apart. The quenching will be lost and
increase in ﬂuorescence is measured. It is a generally accepted fact
that disulﬁde bonds are readily reduced in the cytoplasm by
glutathione. Although it has been proposed that the reduction can
occur in small extent also on the cell membrane of some cells and in
some vesicular compartments mediated by protein disulﬁde isomer-
ase or gamma-interferon-inducible lysosomal thiol reductase [39],
and that the reduction may depend even on the peptide sequence
[40], nevertheless, it has been shown that the vast majority, if not all
of the reduction takes place in the cytoplasm [41]. Therefore, we
measure reduction rate of disulﬁde bonds of cargo-SS-CPP conjugates
which correlates with cytoplasmic delivery of these compounds.
In support of the latter conclusion is the fact that we do not see any
change in the amount of free thiols in extracellular media during
incubation of cells with cargo-SS-CPP conjugates (Fig. 3). This
indicates that the constructs remain intact. Furthermore, this is
consistent with the assumption that in this model system disulﬁde
bonds are not cleaved on the cell membrane in a signiﬁcant amount
and reduction due to possible glutathione outﬂow from the cells is
negligible. Furthermore, if conjugating ﬂuorophore-labeled cargo
peptide with the quencher-labeled cargo peptide we do not observe
uptake either (data not shown). Apart from conﬁrming that our cargo
peptide is indeed membrane impermeable, this further demonstrates
that the disulﬁde bond remains stable in the extracellular media.
Uptake kinetics of other CPPs by principally the same assay has
been assessed before [22] but without using endocytosis inhibitors. In
this study we evaluated effects of these inhibitors on the uptake
kinetics in order to provide information on the uptake mechanism of
the cargo-SS-CPP conjugates. The ﬁrst-order rate constants we
measured are in overall range of 0.2–1.4×10−3 s−1, with corres-
ponding t1/2 values in range of about 15–30 min. The range of mea-
sured rate constants is consistent with some of the previously
published results in the ﬁeld of CPPs where the t1/2 values were
found to be approximately 7, 12, 34 and 58 min for MAP, transportan,
Tat and penetratin, respectively [22]; or 20 min [31] and 45 min [32]
for NBD-labeled penetratin. On the other hand, for some peptides, the
t1/2 values of uptake have been shown to be even less than 2 min
[33,35]. These differences might be a result of different cell types used
in these experiments, different measurement methods, different
labeling techniques and/or different uptake mechanisms that are
exploited by different CPPs. We also measured the amount of
internalized peptide which is in range of 48–534 pmol, corresponding
to 18–60% of the added peptide (see Table 1 and Fig. 4) and these
results are consistent with previously published studies where the
same parameter has been measured [22,31,32].The effect of endocytosis inhibitors on the ﬁrst-order rate
constants and plateau values of the uptake is apparent, with some
common pattern between those two parameters. When the kinetic
constant is signiﬁcantly higher compared to the control, the plateau
value of the uptake is generally lower than the control, and vice versa.
On the other hand, when either of these parameters does not
signiﬁcantly differ from the control, no prediction can be made on the
other parameter. This is a somewhat surprising result since generally
one would expect that lower total penetration is accompanied by also
slower uptake. But in our case, the obtained results indicate
involvement of several different uptake pathways (various endocy-
totic routes, including clathrin mediated endocytosis, macropinocy-
tosis, etc.) of these peptides which give rise to different patterns of
releasing the conjugates into the cytosol. This is also consistent with
previously published results [14–17].
Interestingly, by co-incubating cells with certain inhibitor/CPP
combinations (for example cytochalasin D and TP10; or chlorprom-
azine or cytochalasin D with pVec), the overall uptake of the
conjugates seems to increase rather than decrease as would be
expected from the treatment with an inhibitor. This may further
suggest that different competing pathways may be involved simul-
taneously in the CPP mediated uptake process but with different
efﬁcacies [15], and when one rate-limiting pathway is inhibited, other
pathways may be exploited to a greater extent. This hypothesis
should, however, be tested more thoroughly in future studies in order
to shed light onto this interesting matter.
Fluoresceinyl-labeled pVec-PNA conjugates have previously dis-
played remarkable uptake but almost no biological effect in the
nucleus by a splice correction assay [19]. Also, uptake of ﬂuoresceinyl-
labeled pVec has been shown to decrease by 25% upon wortmannin
treatment in human Bowes melanoma cells [42] but no signiﬁcant
effect of the corresponding inhibitor on the kinetic constant nor the
plateau level of the uptake was observed in our case. Interestingly,
that paper also claims that the uptake of pVec is not signiﬁcantly
affected when the uptake experiments are performed at +8 °C [42].
The differences compared with our results might depend on the
readout used. The cargo must reach the nucleus in order to produce a
biological effect in one case [19] while in the other case registered
total uptake may also contain large portion of signal rising from
endosomaly entrapped CPPs [42]. In our case the main contributor to
the readout is originating from the conjugates that have entered the
cell cytoplasm. Our results suggest involvement of both macropino-
cytosis and clathrin mediated endocytosis in the uptake of cargo-SS-
pVec, although the relative effects of corresponding inhibitors
compared to control remains relatively small and other pathways
(endocytic or direct translocation) cannot be excluded based on our
data.
In case of TP10 we observe signiﬁcant increase in uptake levels by
treating cells with cytochalasin D, and decreased uptake after
treatment with chlorpromazine or wortmannin. This suggests a
predominant involvement of clathrin mediated endocytosis. Lundin
and coworkers [19] reported a similar trend in the splice correction
assay with the same peptide, conjugated to splice correcting PNA. In
addition, we also observe that lower uptake levels correspond to
higher kinetic constants in case of TP10. In other words, the lower
plateau values will be reached in less time and it seems that the
limiting factor in overall uptake is not the maximal rate of a certain
pathway but the overall capability of this pathway to be involved in
this particular active transport pathway.
The M918 peptide displays decreased uptake when the cells are
co-incubated with chlorpromazine, wortmannin, sucrose and cyto-
chalasin D, suggesting both clathrin mediated endocytosis and
macropinocytosis being involved extensively in the cellular delivery
of the cargo peptide. This is consistent with previously published
ﬁnding that the main contributors to the uptake of this peptide when
conjugated to PNA are macropinocytosis and with lesser extent also
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of clathrin mediated endocytosis was observed when the uptake of
M918 was inhibited by sucrose [26]. We also observe lower uptake
values when using inhibitors with corresponding higher kinetic
constants, suggesting that indeed there is more than one pathway
simultaneously involved in the delivery also of this peptide.
In conclusion, by monitoring overall cytoplasmic delivery of CPPs
by a quenched ﬂuorescence assay we show that different CPPs might
exploit different competing endocytotic internalization pathways
simultaneously. Not only uptake levels but also the overall kinetic
proﬁle of the uptake is changed when cells are treated with different
endocytosis inhibitors. We also observe that lower uptake levels often
correlate with higher ﬁrst-order rate constants. This is an important
observation since majority of CPP delivery studies are single time-
point measurements which may not take these specialties into
account when efﬁcacies of different CPPs are elucidated. Our results
also are in accordance with the observation that different entry
pathways may be involved in the delivery of cargo molecules to
different cellular compartments even when using the same CPP.
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